Caseware UK (AP4) 2024.0.164 2024.0.164 2025-03-31 2025-03-31 true The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.2024-04-01 false No description of principal activity 5 false 6 07932529 2024-04-01 2025-03-31 07932529 2023-04-01 2024-03-31 07932529 2025-03-31 07932529 2024-03-31 07932529 c:Director1 2024-04-01 2025-03-31 07932529 c:Director2 2024-04-01 2025-03-31 07932529 c:Director3 2024-04-01 2025-03-31 07932529 c:RegisteredOffice 2024-04-01 2025-03-31 07932529 d:CurrentFinancialInstruments 2025-03-31 07932529 d:CurrentFinancialInstruments 2024-03-31 07932529 c:AuditExempt-NoAccountantsReport 2024-04-01 2025-03-31 07932529 c:FullAccounts 2024-04-01 2025-03-31 07932529 c:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 07932529 c:Micro-entities 2024-04-01 2025-03-31 07932529 e:PoundSterling 2024-04-01 2025-03-31 iso4217:GBP xbrli:pure

Registered number: 07932529 OSTEOPOROSIS RESEARCH LTD FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025
OSTEOPOROSIS RESEARCH LTD COMPANY INFORMATION
Directors | J. Kanis
| R. Kanis-Buck
| E. V. McCloskey
Registered number | 07932529
Registered office | 1st Floor Sackville House
| 143-149 Fenchurch Street
| London
| EC3M 6BL
OSTEOPOROSIS RESEARCH LTD CONTENTS
| Page
Balance Sheet | 1
Notes to the Financial Statements | 2
OSTEOPOROSIS RESEARCH LTD REGISTERED NUMBER: 07932529 BALANCE SHEET AS AT 31 MARCH 2025
|  | 2025 |  | 2024
|  | £ |  | £
Called up share capital not paid |  | 99 |  | 99
Current assets | 282,755 |  | 420,960 |
Creditors: amounts falling due within one year | (13,339) |  | (21,389) |
Net current assets |  | 269,416 |  | 399,571
Net assets |  | 269,515 |  | 399,670
Capital and reserves |  | 269,515 |  | 399,670
The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements. These financial statements have been prepared in accordance with the provisions applicable to entities subject to the micro-entities regime in Part 15 of the Companies Act 2006 and FRS 105: The Financial Reporting Standard applicable to the micro-entities regime. The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The Company has opted not to file the Profit and Loss Account in accordance with the provisions applicable to companies subject to the small companies regime, under section 444 of the Companies Act 2006. The financial statements were approved and authorised for issue by the board and were signed on its behalf on 14 October 2025
J. Kanis
Director
The notes on page 2 form part of these financial statements. Page 1
OSTEOPOROSIS RESEARCH LTD REGISTERED NUMBER: 07932529
1. | General information
Osteoporosis Research Ltd (company number: 07932529) having its registered office at 1st Floor Sackville House, 143-149 Fenchurch Street, London, EC3M 6BL, is a private limited company incorporated in England and Wales.
2. | Employees
The average monthly number of employees, including the directors, during the year was 5 (2024: 6).
3. | Pension commitments
The Company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the Company in an independently administered fund. The pension cost charge represents contributions payable by the Company to the fund and amounted to £703 (2024: £970). Contributions totalling £Nil (2024: £76) were payable to the fund at the Balance Sheet date and are included in creditors.
4. | Related party transactions
| As at the year end, £82,343 (2024: £53,570) was owed from a director of the Company. No interest is chargeable on the balance, which was settled within 9 months of the year end.
Page 2